Response and Amendment under 37 CFR § 1.116 Application No. 10/622,769 Page 2 of 11 Do Not enter ESG 5/29/07

Amendments to Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Ŧ

- 1. (Canceled)
- 2. (Canceled)
- 3. (Currently Amended) A method for treating severe Alzheimer's dementia in a patient in need thereof comprising,

<u>selecting a Alzheimer's dementia patient having a score of 5-9 on the Mini-Mental State</u>

<u>Examination (MMSE); and</u>

administering a compound dosage of 3.0 mg to 10.0 mg daily of donepezil or a pharmaceutically acceptable salt thereof to treat severe Alzheimer's dementia in the patient for a time sufficient to show improvement or no reduction in a cognitive function; wherein severe Alzheimer's dementia is characterized by a score of 5 to 9 on the Mini Mental State Examination.

4. (Currently Amended) A method for treating severe Alzheimer's dementia in a patient in need thereof comprising,

selecting a Alzheimer's dementia patient having a score of 5-9 on the Mini-Mental State

Examination (MMSE); and

administering 10 mg of donepezil hydrochloride to treat severe Alzheimer's dementia in the patient for a time sufficient to show improvement or no reduction in a cognitive function; wherein severe Alzheimer's dementia is characterized by a score of 5 to 9 on the Mini Mental State Examination.

5. (Currently Amended) A method for treating severe Alzheimer's dementia in a patient in need thereof comprising,

<u>selecting a Alzheimer's dementia patient having a score of 5-9 on the Mini-Mental State</u>

<u>Examination (MMSE); and</u>

administering a therapeutically effective amount of donepezil or a pharmaceutically acceptable salt thereof to treat severe Alzheimer's dementia in the patient <u>for a time sufficient to show improvement or no reduction in a cognitive function</u>; wherein severe Alzheimer's dementia is characterized by a score of 5 to 9 on the Mini-Mental State Examination.

Response and Amendment under 37 CFR § 1.116 Application No. 10/622,769 Page 3 of 11

- 6. (Currently amended) The method of claim 5, comprising administering 0.3 mg to 50 mg of donepezil <u>daily</u> or a pharmaceutically acceptable salt thereof to treat severe Alzheimer's dementia in the patient.
- 7. (Currently amended) The method of claim 6, comprising administering 3.0 mg to 10.0 mg of donepezil <u>daily</u> or a pharmaceutically acceptable salt thereof to treat severe Alzheimer's dementia in the patient.
 - 8. (Canceled)
 - 9. (Canceled)
- 10. (Previously presented) The method of claim 3, comprising administering donepezil hydrochloride.
- 11. (Currently amended) The method of claim 3, comprising administering 5 mg of donepezil daily or a pharmaceutically acceptable salt thereof.
- 12. (Currently amended) The method of claim 3, comprising administering 10 mg of donepezil daily or a pharmaceutically acceptable salt thereof.
- 13. (Previously presented) The method of claim 3, comprising administering 5 mg of donepezil hydrochloride to the patient daily for a period of 4 weeks and then administering 10 mg of donepezil hydrochloride to the patient daily.
- 14. (Currently amended) The method of claim 3, wherein the method for treating severe Alzheimer's dementia results in an improvement in the patient's <u>cognitive function</u> score on the Mini-Mental-State Examination.
- 15. (Currently amended) The method of claim 3, wherein the method for treating severe Alzheimer's dementia results in no change in the patient's <u>cognitive function</u> score on the Mini-Mental State Examination.
- 16. (Currently amended) The method of claim 4, wherein the method for treating severe Alzheimer's dementia results in an improvement in the patient's <u>cognitive function</u> score on the Mini-Mental State Examination.
- 17. (Currently amended) The method of claim 4, wherein the method for treating severe Alzheimer's dementia results in no change in the patient's <u>cognitive function</u> score on the Mini-Mental State Examination.

Response and Amendment under 37 CFR § 1.116 Application No. 10/622,769 Page 4 of 11

- 18. (Previously presented) The method of claim 5, comprising administering donepezil hydrochloride.
- 19. (Currently amended) The method of claim 5, comprising administering 0.5 mg to 10 mg of donepezil daily or a pharmaceutically acceptable salt thereof.
- 20. (Currently amended) The method of claim 5, comprising administering 5 mg of donepezil daily or a pharmaceutically acceptable salt thereof
- 21. (Currently amended) The method of claim 5, comprising administering 10 mg of donepezil daily or a pharmaceutically acceptable salt thereof.
- 22. (Currently amended) The method of claim 3, wherein the method for treating severe Alzheimer's dementia results in an improvement in the patient's <u>cognitive function</u> score on the Mini Mental State Examination.
- 23. (Currently amended) The method of claim 3, wherein the method for treating severe Alzheimer's dementia results in no change in the patient's <u>cognitive function</u> score on the Mini-Mental State Examination.